Medical Treatment of Ankylosing Spondylitis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The diagnosis of ankylosing spondylitis is often delayed due to ambiguous clinical manifestations and strictdiagnostic criteria. However, imaging techniques such as magnetic resonance imaging have been found effectivefor the early diagnosis of non-radiographic sacroiliitis. New tumor necrosis factor alpha (TNF-α) inhibitors havegood efficacy for patients with persistently high disease activity despite conventional nonsteroidal antiinflammatorydrug treatment. Thus, early diagnosis and aggressive treatments are essential for ankylosingspondylitis patients. Because many patients complain of musculoskeletal pains, especially around the sacroiliacjoint area, hip specialists should be informed of up-to-date knowledge. In this review, we discuss new diagnosticcriteria for ankylosing spondylitis, administration methods of TNF-αinhibitors, and the long-term follow-upresults for patients treated with TNF-αinhibitors.
Abstract
The diagnosis of ankylosing spondylitis is often delayed due to ambiguous clinical manifestations and strictdiagnostic criteria. However, imaging techniques such as magnetic resonance imaging have been found effectivefor the early diagnosis of non-radiographic sacroiliitis. New tumor necrosis factor alpha (TNF-α) inhibitors havegood efficacy for patients with persistently high disease activity despite conventional nonsteroidal antiinflammatorydrug treatment. Thus, early diagnosis and aggressive treatments are essential for ankylosingspondylitis patients. Because many patients complain of musculoskeletal pains, especially around the sacroiliacjoint area, hip specialists should be informed of up-to-date knowledge. In this review, we discuss new diagnosticcriteria for ankylosing spondylitis, administration methods of TNF-αinhibitors, and the long-term follow-upresults for patients treated with TNF-αinhibitors.
참고문헌 (23)
- van Royen BJ, "Ankylosing spondylitis:diagnosis and management" (2006), Taylor & Francis
- Zochling J, "TNFalpha inhibitors for ankylosing spondylitis", Cochrane Database Systemic Rev, 3, pp.CD005468~ (2005)
- Khan MA, "Update on spondyloarthropathies", Ann Intern Med, 136, pp.896~907 (2002)
- Zochling J, "‘ASsessment in AS’ international working group; European League Against Rheumatism. ASAS", EULAR recommendations for the management of ankylosing spondylitis, 2006, pp.65, 442~452
- Braun J, "New treatment options in spondyloarthropathies : increasing evidence for significant efficacy of anti-tumor necrosis factor therapy", Curr Opin Rheumatol, 13, pp.245~249 (2001)
- Braun J, "2010 update of the ASAS", EULAR recommendations for the management of ankylosing spondylitis, 2011, pp.70, 896~904
- Sieper J, "Ankylosing spondylitis: an overview", Ann Rheum Dis, 61(3), pp.8~18 (2002)
- Rudwaleit M, "Inflammatory back pain in ankylosing spondylitis : a reassessment of the clinical history for application as classification and diagnostic criteria", Arthritis Rheum, 54, pp.569~578 (2006)
- Bennett AN, "Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years", Arthritis Rheum, 58, pp.3413~3418 (2008)
- Haibel H, "Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fiftytwo", Arthritis Rheum, 58, pp.1981~1991 (2008)
- Barkham N, "Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis", Arthritis Rheum, 60, pp.946~954 (2009)
- Evans DM, "Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLAB27 in disease susceptibility", Nat Genet, 43, pp.761~767 (2011)
- Wanders A, "Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial", Arthritis Rheum, 52, pp.1756~1765 (2005)
- El Miedany Y, "The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases", Am J Gastroenterol, 101, pp.311~317 (2006)
- Braun J, "Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis", Arthritis Rheum, 38, pp.499~505 (1995)
- Baraliakos X, "Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome", Rheumatology(Oxford), 50, pp.1690~1699 (2011)
- Martl´n-Mola E, "Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis", Clin Exp Rheumatol, 28, pp.238~245 (2010)
- Baraliakos X, "Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years", Arthritis Res Ther, 15, pp.R67~ (2013)
- Sieper J, "Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis", Ann Rheum Dis, 71, pp.700~706 (2012)
- Khalessi AA, "Medical management of ankylosing spondylitis", Neurosurg Focus, 24, pp.E4~ (2008)
- Bruner V, "Biological therapies for spondyloarthritis", Ther Adv Musculoskelet Dis, 6, pp.92~101 (2014)
- Adams K, "Safety and efficacy of on-demand versus continuous use of nonsteroidal antiinflammatory drugs in patients with inflammatory arthritis : a systematic literature review", J Rheumatol Suppl, 90, pp.56~58 (2012)
- Baraliakos X, "Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab", Arthritis Res Ther, 7, pp.R439~R444 (2005)